Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Senior Vice President, Finance | October 12, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date October 12, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,219 |
Ending reported balance
After 2026-10-12 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2026-10-12 · Exercise / conversion · Acquired 8,541 · Balance 22,760 Row 2 · 2026-10-12 · Exercise / conversion · Acquired 1,458 · Balance 24,218 Row 3 · 2026-10-12 · Sale · Disposed 5,741 · Balance 18,477 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.55 to $80.54, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Row 4 · 2026-10-12 · Sale · Disposed 2,100 · Balance 16,377 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.56 to $81.53, inclusive. Row 5 · 2026-10-12 · Sale · Disposed 1,958 · Balance 14,419 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.61 to $82.50, inclusive. Row 6 · 2026-10-12 · Sale · Disposed 200 · Balance 14,219 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $82.91, inclusive. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2035-01-21 | Direct | 76,376 |
Reported balance
After 2026-10-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-12 · Exercise / conversion · Disposed 8,541 · Balance 76,376 F6: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.39 · Expires 2036-01-22 | Direct | 56,875 |
Reported balance
After 2026-10-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-12 · Exercise / conversion · Disposed 1,458 · Balance 56,875 F7: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.55 to $80.54, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.56 to $81.53, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.61 to $82.50, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $82.91, inclusive.
F6: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
F7: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed May 18, 2026 22:07 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 4,190 | $58.34 | $244,465.13 |
DisclosureSEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 3 Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,506 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.72 to $58.71, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| May 18, 2026 Filed May 18, 2026 22:07 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 5,833 | $34.39 | $200,596.87 |
DisclosureSEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 2 Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2026 Filed May 18, 2026 22:07 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | Exercise / conversionCommon Stock | 2,000 | $12.50 | $25,000.00 |
DisclosureSEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 1 Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:09 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 395 | $41.30 | $16,313.50 |
DisclosureSEC source: 0000907654-26-000032 · form4.xml · nonDerivative · entry 1 Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,863 F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $34.39 | $0.00 |
DisclosureSEC source: 0000907654-26-000016 · form4.xml · derivative · entry 2 Agarwal Arjun · CIK 0002033974 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-01-22 F3 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 22:40 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantCommon Stock | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000907654-26-000016 · form4.xml · nonDerivative · entry 1 Agarwal Arjun · CIK 0002033974 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,258 F1 · shares: The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). F2 · balance_after: Includes 1,758 shares acquired under the Oruka stock purchase plan on December 8, 2025. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:44 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantEmployee Stock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001062993-25-001089 · form4.xml · derivative · entry 1 Agarwal Arjun · CIK 0002033974 · SVP, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.